USING PHARMACOGENETICS TO BETTER EVALUATE NALTREXONE FOR TREATING STIMULANT ABUSE
Pharmacogenetics of Psychostimulant Abuse
Sponsor: National Institute on Drug Abuse
Enrolling: Male and Female Patients
Study Length: 4 Days
Clinic Visits: 8
IRB Number: 7347
U.S. Govt. ID: NCT03226223
Contact: Freymon Perez: 6467746182 / jermaine.jones@nyspi.columbia.edu
Additional Study Information: This study will assess the ability of the opioid antagonist, naltrexone, to block the effects of intranasal methamphetamine. This study is seeking healthy male and female users of psychostimulants like cocaine, methamphetamine between the ages of 21-50. For those who pass screening, the study consists of 4 outpatient testing sessions. Participants are compensated $125 per session.
This study is closed
Investigator
Jermaine Jones, PhD
Do You Qualify?
Recent non-medical use of psychostumulant drugs (e.g., cocaine, methamphetamine) Yes No
Not seeking treatment for substance use disorders (other than nicotine) Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Freymon Perez
jermaine.jones@nyspi.columbia.edu
6467746182